welcome third quarter result conference call today conference record time would like turn conference power vice president investor relation please ahead power vice president investor relation thank good morning everyone thank join third quarter earn call join morning prepare remark board chair chief executive officer chief financial officer also today call chief commercialization officer chief medical officer head global drug development note post slide follow along remark start read forward look statement today call make statement company future plan prospect constitute forward look statement actual result differ materially indicate forward look statement result various important factor include discuss company file forward look statement represent estimate today rely upon represent estimate future date specifically disclaim obligation update forward look statement even estimate change also focus comment financial measure adjust exclude certain specify item reconciliation financial measure comparable measure available hand board chair chief executive officer thank good morning everyone hope turn slide please report good third quarter solid sale growth drive strong commercial execution good progress pipeline proud performance commercial drive demand growth launch product deliver solid performance line product include progress promise asset pipeline sustain growth quarter advance third mechanism dose relatlimab plus accept priority review treatment patient unresectable metastatic melanoma important development franchise additional data readout horizon financial perspective report sale billion growth respectively encourage result position rest future result reaffirm revenue guidance raise lower guidance range balance sheet strong continue pursue discipline capital allocation strategy focus invest internal external innovation opportunity front please decision court appeal federal circle federal circuit uphold provide exclusivity exist settlement decision confirm belief value science behind underlie protect innovation overall extremely please progress quarter turn execution scorecard slide start year scorecard milestone think would important deliver order successfully renew portfolio work hard proud make progress across board number accomplishment include prior slide detail want call highlight provide detail remark start deucravacitinib deucrava demonstrate differentiate profile phase study oral treatment choice psoriasis important asset significant potential across number indication include psoriatic arthritis already initiate phase program although achieve proof concept phase study ulcerative colitis commit advance promise deucravacitinib clinical program inflammatory bowel disease include another study ulcerative colitis disease lupus immune disease continue make great progress cell therapy franchise look forward present transform data second line excite strength data potential enable cell therapy franchise reach broader patient also look forward present data first phase study milvexian prevention patient undergo total knee replacement heart association conference week look oral strength execution confident track deliver require renew portfolio move slide year since form reflect time already make great progress deliver value driver integration importantly establish strong foundation company growth future know face loss exclusivity come year recognize execute multiple launch continue advance pipeline particularly important reflect last year please front strong demand newly launch product deliver promise pipeline include broaden dataset launch product continue progress next generation asset milvexian iberdomide company today diversify ever four durable franchise financial flexibility continue invest innovation recently announce host investor event city review progress last year company strategy pipeline business opportunity look forward meet hope join close make significant progress period would like thank global maintain focus deliver patient turn walk financials chief financial officer thank thank join call today start line performance slide another strong quarter third quarter revenue grow double digit versus prior year primarily demand increase demand line brand product portfolio would light product performance start slide continue perform strongly global sale versus prior year sale grow versus prior year demand growth continue strong total prescription growth versus last year drive large class market share gain growth brand volume sequentially usual sale impact expect coverage liability occur third fourth quarter year expect strong brand share growth translate overall total prescription growth internationally sale grow versus prior year primarily demand share continue increase across geography continue rank multiple market additional room grow remain please execution around world expect continue grow share within grow class move performance slide please continue momentum brand sale growth versus prior year sale grow versus last year primarily drive uptake first line lung cancer multiple launch year sequentially demand growth offset work million inventory build note second quarter commercial continue execute retain strong position core indication melanoma renal please performance newer indication outside another strong quarter sale versus last year growth primarily drive demand indication expand access turkey continue strong uptake launch lung renal cancer price reimbursement discussion ongoing market launch together recent approval first line gastric esophageal cancer expect contribute growth internationally base positive momentum current launch future potential launch include first line esophageal next year expansion opportunity clinical trial read next year promise continue growth high turn line multiple myeloma portfolio slide globally primarily drive demand triple base therapy increase treatment duration global sale drive continue demand triple base therapy earlier line move product slide continue please product generate sale million third quarter diversify portfolio already annualizing close billion rate give great confidence renew business product much earlier lifecycle start generate strong sale million third quarter versus prior year sale growth primarily drive continue demand refractory patient million million inventory build encourage recent guideline update recommend evaluate response sooner eight week instead previously recommend week support need monitor potentially treat patient earlier treatment journey additionally remain focus ensure receive appropriate dose sustain benefit outside uptake continue strong country launch sale impact usual price review year launch expect launch pending reimbursement discussion country drive additional growth brand move cell therapy demand first class remain robust generate million third quarter versus million second quarter remember revenue consist half month sale launch performance quarter reflect full quarter sale demand continue exceed supply expect revenue largely similar move sale quarter million versus million prior quarter sale increase patient demand physician recognize best class profile extremely please clinically meaningful data second line large cell lymphoma look forward present data bring treatment earlier line patient turn global revenue million quarter drive multiple sclerosis launch time inventory build launch continue progress remain choice term write prescription continue focus establish choice also oral treatment choice launch also progress encourage initial uptake growth number trialers since launch focus build volume establish demand oral biologic like medicine broaden access time also please receive positive opinion look forward make available patient live soon possible lastly make progress establish first line maintenance patient generate sale million quarter primarily drive increase demand inventory build versus prior quarter continue focus shape maintenance segment increase adoption patient adherence turn attention slide already cover strong sale quarter walk line item gross margin increase versus prior year primarily lower royalty payment operate expense higher last year particularly recovery also slightly investment support launch launch activity versus prior quarter experience softness time investment shift fourth quarter effective rate primarily drive earn overall increase year year move balance sheet capital allocation slide liquidity position remain strong almost billion cash marketable security strong cash flow operation billion quarter capital allocation priority remain unchanged significant financial flexibility support balance approach capital allocation priority continue renew diversify portfolio business development debt return capital shareholder execute several business development deal year bring differentiate early stage asset business development remain priority lead innovation base company billion debt year date commit maintain strong investment grade relate return capital shareholder commit grow dividend subject board approval remain opportunistic share repurchase already purchase billion share date currently approximately billion remain authorization program turn guidance slide base strong performance quarter reaffirm full year sale raise lower guidance continue expect revenue increase higher guidance gross margin approximately move operate expense maintain guidance year mention earlier expect higher expense fourth quarter time investment shift quarter additionally update rate guidance approximately primarily earn please performance another remarkable quarter company continue execute plan diversify renew portfolio performance could achieve without passion dedication employee around world look forward provide future update progress turn back power vice president investor relation thank first question please